{"id":"W1973354423","doi":"10.1056/nejmoa1314258","title":"Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1964,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"","keywords":"Secukinumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Etanercept; Placebo; Dosing; Dermatology Life Quality Index; Clinical endpoint; Internal medicine; Dermatology; Clinical trial; Psoriatic arthritis; Tumor necrosis factor alpha; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0397480406814782,"score_gpt":0.3245614633366991,"score_spread":0.2848134226552209,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}